Episode 81: Widening the Therapeutic Window in Parkinson Disease

Robert A. Hauser, MD, MBA

Episode 81 of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations
• CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine
• FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data
• FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845
• Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

EPISODE BREAKDOWN

• 1:20 – Lingering unmet needs in Parkinson disease management
• 3:10 – The advances in identifying therapeutic targets in PD
• 4:25 – Bridging the gap to more effective long-term treatment
• 6:00 – Overview of IPX203 and its potential to treat PD
• 7:45 – Neurology News Minute
• 10:15 – Possible advantages of IPX203
• 13:25 – Safety profile of IPX203 in clinical development
• 15:50 – The importance of addressing dose-wearing off
• 16:40 – Closing thoughts

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

• Click here for Apple Podcasts
• Click here for Spotify
• Click here for Google Podcasts